Used in the treatment of secondary progressive multiple sclerosis (SPMS) to reduce the risk of disability progression and slow central nervous system degeneration. It modulates specific sphingosine-1-phosphate receptors to limit the migration of lymphocytes into the central nervous system, thereby reducing neuroinflammation. Employed in oral therapy regimens for adults with active disease, as evidenced by relapses or imaging features.